Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13315: Variant p.Ala350Thr

Serine-protein kinase ATM
Gene: ATM
Feedback?
Variant information Variant position: help 350 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Alanine (A) to Threonine (T) at position 350 (A350T, p.Ala350Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In B-cell chronic lymphocytic leukemia. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 350 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 3056 The length of the canonical sequence.
Location on the sequence: help GKYSSGFRNIAVKENLIELM A DICHQVFNEDTRSLEISQSY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GKYSSGFRNI--AVK----ENLIELMADIC-------------H-QVFNEDTRSLEISQSY

Mouse                         GKYSSGSRNI--AVK----ENLIDLMADIC-----------

Pig                           GKYSSGSRNI--AVK----ENLIELMADIC-----------

Caenorhabditis elegans        TMNEVTRGNIQKLVKTGIQESLKSAHRNFSRSSTFSISEEC

Drosophila                    CKNALLSNN---KFS----DPFIKMSALAM-----------

Baker's yeast                 LPYMIGQENYVEELRS---ESLVSLYREYI-----------

Fission yeast                 SSLSLANFRFHTVEPK---NNIAKLYDPRL-----------

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 3056 Serine-protein kinase ATM
Modified residue 367 – 367 Phosphoserine; by autocatalysis
Mutagenesis 367 – 367 S -> A. Loss of IR-induced S-367 autophosphorylation. Reduced correction of cell cycle checkpoint defects and DNA-repair activity. No effect on S-1893 nor S-1981 autophosphorylation.
Helix 343 – 356



Literature citations
Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.
Stankovic T.; Weber P.; Stewart G.; Bedenham T.; Murray J.; Byrd P.J.; Moss P.A.H.; Taylor A.M.R.;
Lancet 353:26-29(1999)
Cited for: POSSIBLE INVOLVEMENT IN BCLL; VARIANTS THR-350; THR-352; ARG-1054; THR-2274 AND ALA-2695;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.